Journal
CANCER LETTERS
Volume 330, Issue 2, Pages 190-199Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.11.045
Keywords
4.1BB; Melanoma; Peptide vaccines; TLR9
Categories
Funding
- Basic Science Research Program through the National Research Foundation of Korea (NRF)
- Ministry of Education, Science and Technology [2010-0008060]
- National Research Foundation of Korea [2010-0008060] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Peptide vaccines are a clinically applicable therapy shown to be effective in tumor control. In this study, Trp2 peptides plus CpG-oligodeoxynucleotide treatment was found to induce Ag-specific IFN-gamma and CD8+ CTL responses, and antitumor activity against large established melanoma (tumor size, 7 mm). A combination of anti-4.1BB antibodies with Trp2 peptides + CpG-oligodeoxynucleotide increased the antitumor cure rate from 0% to 75%. This effect was concomitant with greater induction of Ag-specific CD8+ CTLs and their infiltration into the tumor sites, highlighting the importance of combined stimulation of TLR9 and 4.1BB for achieving tumor eradication. These findings may have implications for designing peptide-based therapeutic vaccines for cancer-patients. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available